A trial to investigate the neoantigen cancer vaccine GEN-009

Trial Profile

A trial to investigate the neoantigen cancer vaccine GEN-009

Planning
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs GEN 009 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Sep 2017 According to a Genocea Biosciences media release, the company expects to file an Investigational New Drug (IND) application for GEN-009 by early 2018 and plans to initiate a phase I trial in a range of tumor types in the first half of 2018 and expects to report initial immunogenicity data in the first half of 2019.
    • 20 Feb 2017 New trial record
    • 16 Feb 2017 According to a Genocea Biosciences media release, the company expects to file an IND for the neoantigen cancer vaccine GEN-009 by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top